Regulatory T-cells and effects of anti-CTLA4 and anti-PD1 therapy in a transgenic murine model of neuroblastoma

被引：0
|
作者：
Chan, Randall [1 ]
Shirinbak, Soheila [1 ]
Muthugounder, Sakunthala [1 ]
Hung, Long [1 ]
Gnanachandran, Janahan [1 ]
Hajidaniel, Michael [1 ]
Asgharzadeh, Shahab [1 ]
机构：
[1] USC Childrens Hosp Los Angeles, Los Angeles, CA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-5021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5021
引用
收藏
页数：2
相关论文
共 50 条
  • [41] REPROGRAMMING THE INTRAHEPATIC CHOLANGIOCARCINOMA IMMUNE MICROENVIRONMENT BY CHEMOTHERAPY AND CTLA-4 BLOCKADE ENHANCES ANTI-PD1 THERAPY
    Chen, Jiang
    Amoozgar, Zohreh
    Liu, Xin
    Aoki, Shuichi
    Liu, Zelong
    Matsui, Aya
    Pu, Zhangya
    Halvorsen, Stefan
    Lei, Pin-Ji
    Ho, Won Jin
    Huang, Peigen
    Jain, Rakesh
    Bardeesy, Nabeel M.
    Duda, Dan G.
    HEPATOLOGY, 2023, 78 : S106 - S107
  • [42] PD-1 but not CTLA-4 Blockage Abrogates the Protective Effect of Regulatory T Cells in a Pregnancy Murine Model
    Wafula, Paul Ojiambo
    Teles, Ana
    Schumacher, Anne
    Pohl, Kerstin
    Yagita, Hideo
    Volk, Hans-Dieter
    Zenclussen, Ana Claudia
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2009, 62 (05) : 283 - 292
  • [43] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [44] Effects of anti-PD-1 and anti-4-1BB antibody treatment on melanoma-specific T cells in a murine model of melanoma
    Robinson, John L.
    Kodumudi, Krithika
    Weber, Amy
    Samaik, Amod
    Pilon-Thomas, Shari
    CANCER RESEARCH, 2013, 73 (08)
  • [45] INDUCED PLURIPOTENT STEM CELL (IPSC)-BASED VACCINES POTENTIALIZES ANTI-PD-L1 AND ANTI-CTLA4 IMMUNE RESPONSE IN A MURINE TRIPLE NEGATIVE BREAST CANCER MODEL
    Griscelli, F.
    Chaker, D.
    Oudrhiri, N.
    Desterke, C.
    Turhan, A.
    Bennaceur-Griscelli, A.
    CYTOTHERAPY, 2023, 25 (06) : S226 - S226
  • [46] Retrospective analysis of patients with advanced melanoma treated with short course of anti-CTLA4 directly followed by anti-PD-1.
    Rozeman, Elisa A.
    Meerveld-Eggink, Aafke
    Van Thienen, Johannes V.
    Haanen, John B. A. G.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
    Hong, Megan M. Y.
    Vareki, Saman Maleki
    CANCERS, 2022, 14 (06)
  • [48] Flow cytometric analysis of CD4+ T cell reactivation following anti-PD1 immunotherapy in a transgenic mouse model
    Sheriff, Lozan
    Bending, David
    STAR PROTOCOLS, 2022, 3 (01):
  • [49] The role of regulatory T cells in the anti-tumor activity of anti-CTLA-4 antibodies
    Thierry, Kevin
    Menetrier-Caux, Christine
    M S-MEDECINE SCIENCES, 2020, 36 (01): : 73 - 76
  • [50] Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
    Rose, April A. N.
    Armstrong, Susan M.
    Hogg, David
    Butler, Marcus O.
    Saibil, Samuel D.
    Arteaga, Diana P.
    Muniz, Thiago Pimentel
    Kelly, Deirdre
    Ghazarian, Danny
    King, Ian
    Kamil, Zaid Saeed
    Ross, Kendra
    Spreafico, Anna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
12345